Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

12 Issues per year


IMPACT FACTOR 2016: 3.432

CiteScore 2016: 2.21

SCImago Journal Rank (SJR) 2016: 1.000
Source Normalized Impact per Paper (SNIP) 2016: 1.112

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 56, Issue 2

Issues

Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays

María J. Gómara / Javier Rodríguez / María J. Bleda / Juan P. Salvador
  • CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Barcelona, Spain
  • Nanobiotechnology for Diagnostics Group, IQAC-CSIC, Barcelona, Spain
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Raimon Sanmartí / Isabel HaroORCID iD: http://orcid.org/0000-0001-8677-2340
Published Online: 2017-08-29 | DOI: https://doi.org/10.1515/cclm-2017-0264

Abstract

Background:

The objective of the study was to compare the diagnostic yield of home-made ELISA tests based on synthetic chimeric fibrin/filaggrin citrullinated peptides (CFFCPs) with CCP3 and CCP3.1 commercial tests to detect anti-citrullinated protein/peptide antibodies (ACPAs) in rheumatoid arthritis (RA) patients. The prognostic value is also studied in a cohort of patients with early RA. Moreover, we transfer immunological assays from microtiter plates to microarray formats to allow the simultaneous analysis of several peptide sequences and reduce the volume of serum from patients.

Methods:

The diagnostic study includes: 100 RA patients who fulfilled the 1987 ACR criteria; 100 healthy blood donors; 35 patients with SLE according ACR criteria; 35 patients with PsA fulfilling the Wright and Moll criteria and 30 patients with HCV infection. The prognostic value study includes 50 patients with early RA with follow-up data available. All samples are from outpatients attending the Rheumatology Department of the Hospital Clinic of Barcelona.

Results:

Similar sensitivity, specificity and predictive values for the diagnosis of RA of CCFCPs compared to CCP3/CCP3.1 were obtained. Although a high concordance is observed between anti-CFFCPs and anti-CCP3/CCP3.1 in the early patients that rendered Larsen radiographic progression, CFFCPs could be a better marker of radiographic outcome. Strong correlations between the microarray and ELISA results were found for individual CFFCPs peptides.

Conclusions:

The development of multiplexing techniques combining a different spectrum of markers in a single analysis, including CFFCP peptides, could allow a more detailed analysis of the autoantibodies reactivity found in the sera of patients suffering of this heterogeneous disease.

This article offers supplementary material which is provided at the end of the article.

Keywords: rheumatoid arthritis; autoantibodies; chimeric peptides; ELISA; fibrin/filaggrin peptides; microarray

References

  • 1.

    Schellekens GA, de Jong BA, Van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273–81.CrossrefPubMedGoogle Scholar

  • 2.

    van Venrooij WJ, van Beers JJ, Pruijn GJ. Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 2011;7:391–8.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 3.

    Wiik AS, van Venrooij WJ, Pruijn GJ. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010;1:90–3.Web of ScienceGoogle Scholar

  • 4.

    Trouw LA, Mahler M. Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. Autoimmun Rev 2012;12:318–22.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 5.

    Schellekens GA, Visser H, de Jong BA, Van den Hoogen FH, Hazes JM, Breedveld FC, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155–63.PubMedCrossrefGoogle Scholar

  • 6.

    Santiago M, Baron M, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, et al. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. Clin Rheumatol 2008;27:77–83.PubMedWeb of ScienceGoogle Scholar

  • 7.

    Correia ML, Carvalho S, Fortuna J, Pereira MH. Comparison of three anti-CCP antibody tests and rheumatoid factor in RA and control patients. Clin Rev Allergy Immunol 2008;34:21–5.Web of SciencePubMedCrossrefGoogle Scholar

  • 8.

    Swart A, Burlingame RW, Gürtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis. Clin Chim Acta 2012;414:266–72.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 9.

    Szekanecz Z, Szabó Z, Zeher M, Soós L, Dankó K, Horváth I, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res 2013;56:439–43.Web of ScienceCrossrefPubMedGoogle Scholar

  • 10.

    Uysal H, Nandakumar KS, Kessel C, Haag S, Carlsen S, Burkhardt H, et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol Rev 2010;233:9–33.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 11.

    Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GM, van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci 2011;108:17372–7.CrossrefWeb of ScienceGoogle Scholar

  • 12.

    Darrah E, Andrade F. Citrullination, and carbamylation, and malondialdehyde-acetaldehyde! Oh My! Entering the forest of autoantigen modifications in rheumatoid arthritis. Arthritis Rheum 2015;67:604–8.CrossrefGoogle Scholar

  • 13.

    Perez ML, Gomara MJ, Ercilla G, Sanmarti R, Haro I. Antibodies to citrullinated human fibrinogen synthetic peptides in diagnosing rheumatoid arthritis. J Med Chem 2007;50:3573–84.CrossrefWeb of SciencePubMedGoogle Scholar

  • 14.

    Sanmarti R, Graell E, Perez ML, Ercilla G, Vinas O, Gomez-Puerta JA, et al. Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Res Ther 2009;11:R135.Web of SciencePubMedCrossrefGoogle Scholar

  • 15.

    DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.CrossrefPubMedGoogle Scholar

  • 16.

    Hansson M, Mathsson L, Schlederer T, Israelsson L, Matsson P, Nogueira L, et al. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther 2012;14:R201.Web of SciencePubMedCrossrefGoogle Scholar

About the article

Corresponding author: Dr. Isabel Haro, Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Jordi Girona, 18-26, 08034 Barcelona, Spain, Phone: +34 934006109, Fax: +34 932045904


Received: 2017-03-27

Accepted: 2017-07-20

Published Online: 2017-08-29

Published in Print: 2018-01-26


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Financial support from the Spanish Ministry of Economy, Industry and Competitiveness (MINECO) and the European Regional Development Fund (Grant CTQ2015-63919-R).

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 56, Issue 2, Pages 285–293, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2017-0264.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston. Copyright Clearance Center

Supplementary Article Materials

Comments (0)

Please log in or register to comment.
Log in